Sardar Biglari Sells 1,211 Shares of VanEck Biotech ETF (NASDAQ:BBH) Stock

Posted by on Jul 18th, 2026

VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) major shareholder Sardar Biglari sold 1,211 shares of the stock in a transaction on Tuesday, July 14th. The shares were sold at an average price of $16.73, for a total transaction of $20,260.03. Following the completion of the transaction, the insider directly owned 3,559,243 shares in the company, valued at $59,546,135.39. This trade represents a 0.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Sardar Biglari also recently made the following trade(s):

  • On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30.
  • On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43.

VanEck Biotech ETF Price Performance

VanEck Biotech ETF stock opened at $204.23 on Friday. VanEck Biotech ETF has a fifty-two week low of $154.75 and a fifty-two week high of $212.54. The stock has a 50-day simple moving average of $193.07 and a 200-day simple moving average of $191.95.

Institutional Investors Weigh In On VanEck Biotech ETF

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of VanEck Biotech ETF by 40,463.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after acquiring an additional 492,843 shares during the period. Raymond James Financial Inc. raised its position in VanEck Biotech ETF by 2.8% in the 3rd quarter. Raymond James Financial Inc. now owns 69,809 shares of the company’s stock valued at $11,566,000 after purchasing an additional 1,869 shares during the last quarter. Bank of America Corp DE raised its position in VanEck Biotech ETF by 44.3% in the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after purchasing an additional 20,375 shares during the last quarter. Ascent Advisors LLC acquired a new stake in VanEck Biotech ETF during the 1st quarter worth $11,178,000. Finally, LPL Financial LLC boosted its stake in VanEck Biotech ETF by 63.5% during the 4th quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock worth $6,021,000 after purchasing an additional 12,351 shares during the period. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

(Get Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

Recommended Stories

Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.